Jeffrey Wager, M.D., Chairman
Jeff has over 25 years of senior operating experience in the life sciences, beginning in 1991-1995 with a unit of the Bank of Tokyo, advising Japanese pharma clients on international clinical development & strategic alliances.
From 1995-2000, he was with Medical Science Partners (a Harvard-sponsored VC fund), which invested $100M over two funds, including seed/Series A investments in ICAgen, Inspire, deCODE, Oravax/Acambis, ZYCOS, amongst others. In 2000, he founded and has since led Apeiron Parthers, LLC, a FINRA-registered investment bank focused on corporate spin-outs, completing six to date (including Targacept, Inc. (from RJR), Artisan Pharma, Inc. (from Asahi) and Biocritica (from Lilly)), as well as a variety of other strategic transactions and company formations.
From 2003-06, he was the advisor to the establishment and investment of Z-Cube s.r.l., the €60 million corporate VC arm of the Zambon Group (Italy). Between 2006-10, he formed and led Artisan Pharma, Inc. as its founding CEO, raising $53 million, building the entire team and co-designing and managing a 750 patient, 17 country Phase 2b/3 critical care study, leading to Artisan’s acquisition in 2011. Between 2011 – 2016, he was the principal advisor on the sale of United Medical Ltda. (Brazil) to Biotoscana and a board observer to the resulting Grupo Biotoscana SL, a leading Latin American specialty pharma roll-up financed by Advent International & Essex Woodlands Healthcare Ventures.
Through his role at Apeiron, Jeff is also a co-founder and chairman of EnBiotix, Inc., an engineered antibiotics company. Jeff earned his M.D. at Rush Medical College and his MBA from the University of Chicago.